Effects of continuous positive airway pressure therapy on plasma aldosterone levels in patients with obstructive sleep apnea: A meta-analysis

Abstract

Obstructive sleep apnea (OSA) is an independent risk factor for cardiovascular diseases. Aldosterone was reported to be increased in patients with OSA and correlated with OSA severity. Many studies investigated the effect of continuous positive airway pressure (CPAP) therapy on plasma aldosterone concentrations (PAC) in OSA patients. The results, however, were inconsistent. In the present study, we aimed to evaluate the effects of CPAP therapy on PAC by performing a meta-analysis. Literature search was carried out in electronic databases including PubMed/Medline, Cochrane Library, Embase and Web of Science. Eligible full-text articles were identified, and important data were extracted. Pooled analysis was performed using the STATA12.0 and RevMan 5.2. Standardized mean difference (SMD) was calculated to estimate the treatment effects. A total of eight studies involving 219 patients were included for our final analysis. PAC was found unchanged after CPAP treatment in OSA patients (SMD=–0.36, 95% CI:–0.91 to 0.18, Z=1.32, P=0.19). Meanwhile, CPAP therapy showed no impact on PAC (SMD=–0.21, 95% CI:–0.85 to 0.42, Z=0.66, P=0.51) in a separate meta-analysis including 3 randomized controlled trials. In conclusion, the evidence for the use of CPAP therapy to decrease PAC in OSA patients is low, and further studies are still warranted.

Keywords

obstructive sleep apnea / continuous positive airway pressure / aldosterone / meta-analysis

References

[1] YoungT, PaltaM, DempseyJ, et al. . The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med, 1993, 328(17): 1230-1235 PMID: 8464434

[2] McNicholasWT, BonsignoreMR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J, 2007, 29(1): 156-178 PMID: 17197482

[3] YoshimotoT, HirataY. Aldosterone as a cardiovascular risk hormone. Endocr J, 2007, 54(3): 359-370 PMID: 17409575

[4] Di MurroA, PetramalaL, CotestaD, et al. . Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin-Angio-Aldo S, 2010, 11(3): 165-172

[5] BarceloA, PierolaJ, EsquinasC, et al. . Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PloS one, 2014, 9(1): 84362

[6] MllerDS, LindP, StrungeB, et al. . Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens, 2003, 16(4): 274-280

[7] Pratt-UbunamaMN, NishizakaMK, BoedefeldRL, et al. . Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest, 2007, 131(2): 453-459 PMID: 17296647

[8] LloberesP, SampolG, EspinelE, et al. . A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea. J Hypertens, 2014, 32(8): 1650-1657 PMID: 24879492

[9] GaddamK, PimentaE, ThomasSJ, et al. . Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens, 2010, 24(8): 532-537 PMID: 20016520

[10] JenkinsonC, DaviesRJ, MullinsR, et al. . Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet, 1999, 353(9170): 2100-2105 PMID: 10382693

[11] MarinJM, CarrizoSJ, VicenteE, et al. . Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet, 2005, 365(9464): 1046-1053 PMID: 15781100

[12] WangJY, YuWY, GaoMX, et al. . Continuous positive airway pressure treatment reduces cardiovascular death and non-fatal cardiovascular events in patients with obstructive sleep apnea: A meta-analysis of 11 studies. Int J Cardiol, 2015, 191: 128-131 PMID: 25965619

[13] ZieglerMG, MillsPJ, LoredoJS, et al. . Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest, 2001, 120(3): 887-893 PMID: 11555525

[14] SteiropoulosP, KotsianidisL, NenaE, et al. . Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep, 2009, 32(4): 537-543 PMID: 19413148 PMCID: 2663658

[15] IpMSM, TseHF, LamB, et al. . Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med, 2004, 169(3): 348-353 PMID: 14551167

[16] NichollDD, HanlyPJ, PoulinMJ, et al. . Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med, 2014, 190(5): 572-580 PMID: 25033250

[17] ZhangXL, LiYQ. Efficacy of continuous positive airway pressure therapy upon resistant hypertension in patients with obstructive sleep apnea hypopnea syndrome. Zhonghua Yi Xue Zha Zhi (Chinese), 2009, 89(26): 1811-1814

[18] LacedoniaD, TamisierR, RocheF, et al. . Respective effects of OSA treatment and angiotensin receptor blocker on aldosterone in hypertensive OSA patients: A randomized cross-over controlled trial. Int J Cardiol, 2014, 177(2): 629-631 PMID: 25443257

[19] SaarelainenS, HasanJ, SiitonenS, et al. . Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res, 1996, 5(3): 181-185 PMID: 8956208

[20] MestonN, DaviesRJ, MullinsR, et al. . Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. J Intern Med, 2003, 254(5): 447-454 PMID: 14535966

[21] ShrierI, BoivinJF, SteeleRJ, et al. . Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol, 2007, 166(10): 1203-1209 PMID: 17712019

[22] HozoSP, DjulbegovicB, HozoI. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005, 5: 13 PMID: 15840177 PMCID: 1097734

[23] SvatikovaA, OlsonLJ, WolkR, et al. . Obstructive sleep apnea and aldosterone. Sleep, 2009, 32(12): 1589-1592 PMID: 20041594 PMCID: 2786042

[24] RodensteinDO, D’OdemontJP, PietersT, et al. . Diurnal and nocturnal diuresis and natriuresis in obstructive sleep apnea. Effects of nasal continuous positive airway pressure therapy. Am Rev Respir Dis, 1992, 145(6): 1367-1371 PMID: 1596005

[25] FolleniusM, KriegerJ, KrauthMO, et al. . Obstructive sleep apnea treatment: peripheral and central effects on plasma renin activity and aldosterone. Sleep, 1991, 14(3): 211-217 PMID: 1896722

[26] HuX, KangJ, XiaoD, et al. . The influence of nasal continual positive airway pressure on some vasoactive substances in patients with obstructive sleep apnea syndrome. Zhonghua Jie He He Hu Xi Za Zhi (Chinese), 2002, 25(1): 36-38

[27] AkashibaT, OtsukaK, YoshizawaT, et al. . Effects of nasal continuous positive airway pressure (NCPAP) on nocturnal renal function in obstructive sleep apnea syndrome (OSAS). Nihon Kyobu Shikkan Gakkai Zasshi, 1991, 29(5): 573-577 PMID: 1886297

[28] NishijimaT, TajimaK, TakahashiK, et al. . Elevated plasma levels of soluble (pro)renin receptor in patients with obstructive sleep apnea syndrome: Association with polysomnographic parameters. Peptides, 2014, 56: 14-21 PMID: 24657284

[29] JiXC, ZhaoWH, CaoDX, et al. . Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1. Acta Pharmacol Sin, 2011, 32(2): 182-187 PMID: 21293470 PMCID: 4009930

[30] XiaoY, YinK, ZhengP. Significance of the changes of urinary uric acid, ANP, renin and aldosterone in sleep apnea syndrome patients. Zhonghua Jie He He Hu Xi Za Zhi (Chinese), 2000, 23(1): 27-30

[31] WolfJ, LewickaJ, NarkiewiczK. Obstructive sleep apnea: an update on mechanisms and cardiovascular consequences. Nutr Metab Cardiovasc Dis, 2007, 17(3): 233-240 PMID: 17314035

[32] FletcherEC, BaoG, LiR. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension, 1999, 34(2): 309-314 PMID: 10454459

[33] FletcherEC, OrolinovaN, BaderM. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol, 2002, 92(2): 627-633 PMID: 11796674

[34] GoodfriendTL, CalhounDA. Resistant hypertension, obesity, sleep apnea, and aldosterone -Theory and therapy. Hypertension, 2004, 43(3): 518-524 PMID: 14732721